---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000033"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:09:06.841220+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Xeris closes $150M Hayfin debt facility, reports FY2021 product revenue $79M (+56%) and guides FY2022 $105M-$120M

## Summary
- Xeris drew $100M from new $150M Hayfin term loan (9%+SOFR, warrants at $2.28, 5-yr maturity); repaid $43.5M Oxford/SVB debt.
- FY2021 net product revenue $79M (pro forma), up 56% YoY; net loss $122.7M ($1.55/share) vs $91.1M ($2.14/share) in 2020.
- FY2022 revenue guidance $105M-$120M; year-end cash $90M-$110M; cash flow breakeven targeted by end of 2023.
- Gvoke prescriptions up 85% in Q4, retail share ~17%; Keveyis at high end of $38-40M guidance; Recorlev launched Feb 2022.

## SEC filing metadata
- accession: 0001867096-22-000033
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000033/0001867096-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000033/xers-20220308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000033
- JSON: https://secwatch.observer/filing/0001867096-22-000033.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.